SYGNIS AG launches TruePrime® apoptotic cell free DNA amplification kit for the liquid biopsy market
December 6th, 2017
Heidelberg, Germany and Cambridge, UK, 06 December 2017 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced the launch of its TruePrime® apoptotic cell free DNA amplification kit, under the Expedeon brand. The kit enables accurate DNA amplification using cell free DNA (cfDNA) obtained from plasma, serum, urine, cerebrospinal fluid (CSF), or many other bodily fluids.
Dr. Heikki Lanckriet, CEO and CSO of SYGNIS AG, commented: “This new TruePrime® apoptotic cell free DNA amplification kit launch comes at a very important period in the growing liquid biopsy market, as applications for the liquid biopsy market will become an important growth driver for Sygnis. The technology contains the latest advances in amplification techniques, sensitivity and simplicity. The addition of this kit to our portfolio supports our contribution to the global effort to discover the genetic cancer markers, which are vital for successful treatments and cures. Additionally, we are further strengthening our IP position around this technology and process.”
The TruePrime® apoptotic cell free DNA amplification kit uses a novel multiple displacement amplification method to overcome the common limitations with the analysis of bodily fluid for cell free DNA analysis. By exponentially amplifying cell-free DNA derived from apoptosis, the cell-death mechanism, these TruePrime® kits provide users with excellent sensitivity, error-free amplification in high yields, and a streamlined workflow for reduced hands-on time.
The new technology expands the Company’s range of TruePrime® kits, further strengthening its offering within the growing liquid biopsy market, which is set to increase at a CAGR of 23% by 2022. Kits and consumables are the leading sub-segment to the global liquid biopsy market value. Key factors driving this market include the demand for the detection and monitoring of cancer, which is increasing alongside disease prevalence. The new technology has potential to meet this demand through its use in Next Generation Sequencing (NGS)-based clinical diagnostics.
About SYGNIS AG: www.sygnis.com
SYGNIS develops and commercialises value-added, easy-to-use, reliable products for genomics and proteomics research based on its proprietary technologies, offering a wide range of solutions that address key challenges in molecular biology. With applications spanning the entire molecular biology workflow, the Group’s cutting-edge offerings include easy-to-use off-the-shelf products as well as custom services, supporting scientists from academia through to commercial manufacturing. SYGNIS’ products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. SYGNIS AG has offices in Germany, Spain, UK, USA and Singapore which trade under the Expedeon, Expedeon and C.B.S. Scientific brands. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).